NCT00204581View on ClinicalTrials.gov

Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

January 31, 2009

Study Completion Date

December 31, 2009

Conditions
Melanoma
Interventions
DRUG

Interleukin-2 (Proleukin)

6-12 MIE/d 3times a week

Trial Locations (1)

72076

Skin Cancer Program, Department of Dermatology, Liebermeisterstrasse 8, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER

NCT00204581 - Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases | Biotech Hunter | Biotech Hunter